ResMed (NYSE: RMD, ASX: RMD) has announced the acquisition of privately held Somnoware, a U.S. leader in sleep and respiratory care diagnostics software. Somnoware software streamlines the processes of physicians as well as sleep and pulmonary function testing labs for diagnosing and evaluating a patient’s sleep and respiratory care test results, ordering PAP treatment equipment, setting up appointments, tracking PAP compliance, and electronically providing this information directly into a patient’s electronic health record – all from within the Somnoware platform.
Read the full article: ResMed Acquires Somnoware, a Leader in Digital Sleep and Respiratory Care Diagnostics Software //
Source: https://www.globenewswire.com/news-release/2023/07/05/2699917/0/en/ResMed-Acquires-Somnoware-a-Leader-in-Digital-Sleep-and-Respiratory-Care-Diagnostics-Software.html